Meta-analiz priema 200 ili 600 mg mifepristona v sochetanii s dvumya vidami prostaglandinov dlya preryvaniya beremennosti na rannikh srokakh (original'naya nauchnaya stat'ya)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

There is unsettled controversy about the respective efficacy and safety of 200 and 600 mg mifepristone in combination with two prostaglandins for the termination of pregnancy up to 63 days’ gestation. We performed a meta-analysis of randomized controlled trials (RCTs) of direct comparisons between the two dose regimens. End points were complete abortion, continuing pregnancy and side effects. Four RCTs (3482 patients) were found. Noninferiority of 200 mg mifepristone compared with 600 mg was proven for complete abortion (difference, 0.4 %; 95 % confidence interval [CI] = -1.4 % to 2.3 %). Noninferiority was not proven for continuing pregnancy (difference, 0.4 %; 95 % CI = -0.3 % to 1.0 %). Two hundred milligrams may therefore result in 1 % more continuing pregnancies than 600 mg when used with the approved prostaglandin regimens. Sensitivity analyses confirmed the findings. There was no difference in adverse events between both doses of mifepristone. Although 200 or 600 mg of mifepristone with two prostaglandins probably results in similar rates of complete abortion, the substitution of 200 mg for 600 mg may lead to an increased continuing pregnancy rate.

Full Text

Restricted Access

References

  1. WHO. Global and regional estimates of the incidence of unsafe abortion and associated mortality in 2000. 4th ed. Geneva: World Health Organization; 2004. Available from: http:// www.who.int/reproductivehealth/publications/ unsafeabortion_2003/ua_estimates03.pdf.
  2. WHO. Model list of essential medicines. 15th ed. Geneva: World Health Organization; 2007. Available from: http://www.who.int/medicines/publications/EssMedList15.pdf.
  3. Sitruk-Ware R. Mifepristone and misoprostol sequential regimen: side effects, complications and safety. Contraception. 2006;74:48-55.
  4. Ulmann A., Silvestre L., Chemama L., et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstet. Gynecol. Scand. 1992;71:278-83.
  5. Aubeny E., Peyron R., Turpin C.L., et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int. J. Fertil. Menopausal Stud. 1995;40(Suppl 2):85-91.
  6. Spitz I.M., Bardin C.W., Benton L., Robbins A. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N. Engl. J. Med. 1998;21:1509-13.
  7. WHO Task Force on Post-Ovulatory Methods for Fertility Regulation. Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG. 2001; 108:738-42.
  8. Schaff E.A., Fielding S.L., Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002;66:247-50.
  9. von Hertzen H., Honkanen H., Piaggio G., et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG. 2003;110:808-18.
  10. von Hertzen H. Research on regimens for early medical abortion. J Am Med Womens Assoc 2000;55(3 Suppl):133-36.
  11. Ashok P.W., Penney G.C., Flett G.M., Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum. Reprod. 1998;13:2962-65.
  12. Schaff E.A., Fielding S.L., Eisinger S.H., Stadalius L.S., Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception. 2000;61:41-6.
  13. Schaff E.A., Fielding S.L., Westhoff C., et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion. A randomized trial. JAMA. 2000;284:1948-53 [Erratum in: JAMA;284:2597].
  14. Bartley J., Brown A., Elton R., Baird D.T. A double blind randomized control trial between vaginal gemeprost and misoprostol in combination with mifepristone for induction of abortion in early pregnancy. Hum. Reprod. 2001;16:2098-102.
  15. Ashok P.W., Templeton A., Wagaarachchi P.T., Flett G.M. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. BJOG. 2002;109:1281-89.
  16. Kulier R., Gulmezoglu A.M., Hofmeyr G.J., Cheng L.N., Campana A. Medical methods for first trimester abortion. Cochrane Database Syst. Rev. 2004(1):CD002855.
  17. Agence Nationale d'Accreditation et d'Evaluation en Sante (ANAES). Prise en charge de l'interruption volontaire de grossesse jusqu'a 14 semaines. Paris: Agence Nationale D'accreditation et D'avaluation en Sante; 2001.
  18. National Abortion Federation (NAF). Early medical abortion with mifepristone and other agents: overview and protocol recommendations. Washington (DC): National Abortion Federation; 2002.
  19. WHO. Safe abortion: technical and policy guidance for health systems. Geneva: World Health Organization; 2003.
  20. Royal College of Obstetricians and Gynaecologists (RCOG). The care of women requesting induced abortion. Evidence-based clinical guideline N 7. London: RCOG Press; 2004.
  21. WHO Task Force on Post-Ovulatory Methods for Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. Br. Med. J. 1993;307:532-37.
  22. Peyron R., Aubeny E., Targosz V., et al. Early termination of pregnancy with mifepristone (RU486) and the orally active prostaglandin misoprostol. N. Engl. J. Med. 1993; 328:1509-13.
  23. McKinley C., Thong K.J., Baird D.T. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum. Reprod. 1993;8: 1502-505.
  24. WHO Task Force on Post-Ovulatory Methods for Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG. 2000;107:524-30.
  25. Sitruk-Ware R., Davey A., Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet. 1998;352:323.
  26. Aronoff D.M., Hao Y., Chung J., et al. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J. Immunol. 2008;180(12):8222-30.
  27. Aronsson A., Fiala C., Stephansson O., et al. Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol. Hum. Reprod. 2007;22: 1912-18.
  28. Winikoff B., Dzuba I.G., Creinin M.D., et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet. Gynecol. 2008;112:1303-10.
  29. El-Refaey H., Templeton A. Early induction of abortion by a combination of oral mifepristone and misoprostol administered by the vaginal route: a comparison between two dose regimens of misoprostol and their effect on blood pressure. Br. J. Obstet. Gynaecol. 1994; 101:792-96.
  30. El-Refaey H., Rajasekar D., Abdalla M., et al. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N. Engl. J. Med. 1995;332:983-87.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies